Betaine
- Generic Name
- Betaine
- Brand Names
- Amversio, Cystadane, EnBrace HR, EnLyte
- Drug Type
- Small Molecule
- Chemical Formula
- C5H11NO2
- CAS Number
- 107-43-7
- Unique Ingredient Identifier
- 3SCV180C9W
- Background
Betaine is a methyl group donor that functions in the normal metabolic cycle of methionine. It is a naturally occurring choline derivative commonly ingested through diet, with a role in regulating cellular hydration and maintaining cell function. Homocystinuria is an inherited disorder that leads to the accumulation of homocysteine in plasma and urine. Curre...
- Indication
Betaine is indicated for the treatment of homocystinuria in pediatric and adult patients to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), and cobalamin cofactor metabolism (cbl).
- Associated Conditions
- Homocystinuria, Homocystinuria Due to Cystathionine Beta-Synthase Deficiency, Homocystinuria due to MTHFR deficiency, Homocystinuria due to cobalamin cofactor metabolism (cbl) defect
- Associated Therapies
- -
The Therapeutic Effect of Betaine in Syringomyelia
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Xuanwu Hospital, Beijing
- Target Recruit Count
- 30
- Registration Number
- NCT06308367
- Locations
- 🇨🇳
Fengzeng Jian, Beijing, Beijing, China
Betaine METABOLISM OF PATIENTS With Homocystinuria
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 12
- Registration Number
- NCT02404337
- Locations
- 🇫🇷
Assistance Publique - Hôpitaux de Paris, Paris, France
Metabolic Effects of Betaine Supplementation
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Joslin Diabetes Center
- Target Recruit Count
- 28
- Registration Number
- NCT01950039
- Locations
- 🇺🇸
Joslin Diabetes Center and Brigham and Womens Hospital, Boston, Massachusetts, United States
Betaine and Peroxisome Biogenesis Disorders
- First Posted Date
- 2013-04-24
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Target Recruit Count
- 12
- Registration Number
- NCT01838941
- Locations
- 🇨🇦
Montreal Children's Hospital, Montreal, Quebec, Canada
A Preliminary Study of Choline and Betaine Supplementation Among Adults Exposed to Arsenic in Bangladesh
- Conditions
- Interventions
- First Posted Date
- 2012-12-17
- Last Posted Date
- 2014-08-28
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 60
- Registration Number
- NCT01749982
- Locations
- 🇧🇩
Columbia University Arsenic Research Project, Dhaka, Bangladesh
Pilot Study of Betaine + Combination Antiviral Therapy for Chronic Hepatitis C Genotype 1 Non-responder/Relapsers
- Conditions
- Interventions
- First Posted Date
- 2009-04-16
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 2
- Registration Number
- NCT00882193
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Dietary Supplements for the Treatment of Angelman Syndrome
- Conditions
- Interventions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2012-09-24
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 90
- Registration Number
- NCT00348933
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
🇺🇸Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸Children's Hospital Boston, Boston, Massachusetts, United States
Chronic Hepatitis C Non-Responder Study With AdoMet and Betaine
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2010-10-28
- Lead Sponsor
- University Hospital, Basel, Switzerland
- Target Recruit Count
- 30
- Registration Number
- NCT00310336
- Locations
- 🇨🇭
University Hospital Basel, Basel, BS, Switzerland
Efficacy of Betaine for Reduction of Urine Oxalate in Patients With Type 1 Primary Hyperoxaluria
- First Posted Date
- 2006-01-27
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 15
- Registration Number
- NCT00283387
- Locations
- 🇺🇸
Mayo Clinic Hyperoxaluria Center, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.